{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-230710","form_type":"8-K","ticker":"EBS","cik":"0001367644","company_name":"Emergent BioSolutions Inc.","filed_at":"2024-10-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.266983+00:00","generated_at":"2026-05-30T22:14:28.471264+00:00","sec_items":["1.01","2.02","2.03","7.01","9.01"],"event_type":"debt","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Emergent BioSolutions closes $100M ABL credit facility, reports $150M cash balance","bullets":["New asset-based revolving loan facility of up to $100M, maturing September 2029.","Cash balance of approximately $150M as of September 30, 2024.","ABL facility undrawn at closing; provides additional liquidity for transformation plan.","Facility follows prior $250M term loan refinancing with Oak Hill Advisors in September 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-230710","json":"https://secwatch.observer/filing/0001193125-24-230710.json","markdown":"https://secwatch.observer/filing/0001193125-24-230710.md","text":"https://secwatch.observer/filing/0001193125-24-230710.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1367644/000119312524230710/0001193125-24-230710-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1367644/000119312524230710/d825659d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T22:14:28.471264+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}